Iodonium salts have shown great potential as metal-free reagents in various transformations, offering a promising alternative to transition-metal-catalyzed arene amination. Herein, we report the design and synthesis of chromone-based iodonium salts (CMISs) and demonstrate their efficiency in selective chromone amination. Unlike the conventional ligand exchange/coupling pathway, mechanistic studies reveal a unique amination pathway specific to the chromone scaffold, in which the aryliodonium unit simultaneously facilitates N-Michael addition and the formation of a newfound chromone-derived strained alkyne intermediate, leading to mechanistic competition while directing product configuration. By further modulating the basicity and steric hindrance of amines, three distinct classes of aminated products ((Z)-2-(aminomethylene)-benzofuranones, β-aminochromones and α-aminochromones) were accessed.
Atropisomerism and restricted amide CO–N bond rotation are commonly encountered structural characteristics in drug discovery and development. Inspired by the unusual NMR spectra of soticlestat (S-1), a CYP46A1 inhibitor currently under development in phase 3 clinical trials, soticlestat and its 14 structurally close analogs were designed, synthesized and studied by variable-temperature 13C NMR, molecular mechanics, quantum mechanics and HPLC to explore the structural characteristics that affect the restricted bond rotations and the number of stable conformations. It is concluded that there are four stable conformations at room temperature which exist as two diastereomers each as a pair of enantiomers, and the interconversion rates of these conformations are intermediate on the NMR time scale but are inseparable by HPLC, justifying that soticlestat can be developed as a mixture of four rotational isomers.
The COVID-19 pandemic has significantly strained global health infrastructures while profoundly affecting the socio-economic landscape. RNA-dependent RNA polymerase (RdRp) plays a pivotal role in the replication and transcription of RNA viruses, making it a critical target for antiviral drug development. In this work, we describe the discovery, rational optimization, and synthesis of a novel series of non-nucleoside SARS-CoV-2 RdRp inhibitors featuring a 2,2'-((1H-indole-2,3-diyl)bis (thio))diacetamide core. The inhibitory activity of these compounds was evaluated, with most demonstrating a higher inhibitory effect than Remdesivir. Notably, the most potent candidates suppressed RNA synthesis dose-dependently and exhibited greater resistance to nsp14/nsp10 exonuclease-mediated proofreading compared to Remdesivir. Furthermore, 10b6 and 10b12 showed 1.6- to 2-fold lower EC50 values against coronavirus HCoV-OC43 than Remdesivir, highlighting their potential for further development as broad-spectrum antiviral agents.
DNA polymerase theta (Polθ or POLQ) is an attractive target for treating BRCA-deficient cancers. In the present work, several computational approaches were employed for the design and discovery of novel POLQ helicase domain inhibitors. A dataset was constructed by curating a total of 781 known inhibitors, which were used to develop binary classification models using random forests to distinguish between highly and weakly active inhibitors. The Matthews correlation coefficient of the consensus model reached 0.771 for the test set. A virtual screening procedure of 3.4 million molecules was conducted based on shape similarity and predictions from the consensus model to identify four hits and a favorable benzothiazole moiety. A molecular generation model was trained using molecules from both the curated dataset and the identified hits to generate potential inhibitors, which were subsequently predicted by the consensus model. Finally, eight compounds were selected and synthesized for biochemical testing, leading to the identification of compound 19, which had a novel scaffold and acceptable potency: inhibition rates of 80.7
INTRODUCTION: Cholangiocarcinoma (CCA) is a highly aggressive biliary malignancy with a very poor prognosis. How to screen the optimal chemotherapy regimen is crucial for enhancing the prognosis of CCA patients. The study aims to develop patient-derived tumor organoid (PDO) models and patient-derived tumor xenograft (PDX) models of CCA to simulate clinical responses to chemotherapy. METHODS: Tumor tissues were collected from patients undergoing surgical resection and subsequently utilized to establish PDO and PDX models. Hematoxylin-eosin (H&E), immunohistology (IHC), and immunofluorescence (IF) were conducted to analyze the biological characteristics of these PDXs and PDOs. Whole exome sequencing (WES) was performed to identify the mutation types of primary tumor, PDO, and PDX. Drug sensitivity assays were conducted utilizing PDO and PDX models to compare clinical treatment responses. RESULTS: In this study, we successfully established 18 PDO (success rate, 56.3%) models and 21 PDX models (success rate, 65.6%) from 32 patients diagnosed with CCA. PDO and PDX preserved the mutational profiles characteristic of the primary tumor samples. The drug screening results from PDOs demonstrated a correlation with the actual clinical response to chemotherapy regimens, and these findings were further validated in PDX models. CONCLUSIONS: Our findings indicate that the integration of PDO and PDX models can successfully guide clinical treatment strategies, facilitating effective personalized therapy for CCA patients.